Literature DB >> 25876744

[Treatment of atrial fibrillation in intensive care units and emergency departments].

M Arrigo1,2, D Bettex2, A Rudiger3.   

Abstract

BACKGROUND: Atrial fibrillation is the most common arrhythmia in patients hospitalized in intensive care units and emergency departments and is associated with an increased morbidity and mortality. In critically ill patients, atrial fibrillation can cause hemodynamic instability and cardiogenic shock. The mechanisms and the management of atrial fibrillation are significantly different in critically ill patients compared to outpatients. DIAGNOSIS AND TREATMENT: The initial management includes the evaluation of the hemodynamic consequences of new-onset atrial fibrillation and the optimization of reversible causes. In patients with hemodynamic instability the rapid restoration of an adequate perfusion pressure is the initial goal. Often, a rapid conversion in sinus rhythm is required to achieve hemodynamic stabilization. Electrical cardioversion, if possible performed after pretreatment with an antiarrhythmic drug to increase the success rate, frequently plays a central role in the conversion to sinus rhythm of hemodynamically unstable patients. Stable patients are initially treated with a short-acting intravenous β-blocker to achieve heart rate control. A conversion to sinus rhythm may be achieved pharmacologically with vernakalant, an atrial-specific multichannel blocker. EVALUATION: All patients with atrial fibrillation lasting more than 48 h should be evaluated for anticoagulation in order to reduce cardio-embolic complications. After recovering from the acute illness, atrial fibrillation persists only in a minority of patients.

Entities:  

Keywords:  Cardioversion; Critically ill; Esmolol; Intensive care unit; Vernakalant

Mesh:

Substances:

Year:  2015        PMID: 25876744     DOI: 10.1007/s00063-015-0006-2

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  30 in total

Review 1.  Thyroid hormone and the cardiovascular system.

Authors:  I Klein; K Ojamaa
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

Review 2.  Amiodarone for atrial fibrillation.

Authors:  Peter Zimetbaum
Journal:  N Engl J Med       Date:  2007-03-01       Impact factor: 91.245

3.  A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.

Authors:  A John Camm; Alessandro Capucci; Stefan H Hohnloser; Christian Torp-Pedersen; Isabelle C Van Gelder; Brian Mangal; Gregory Beatch
Journal:  J Am Coll Cardiol       Date:  2011-01-18       Impact factor: 24.094

4.  Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion.

Authors:  G Opolski; J Stanisławska; A Górecki; G Swiecicka; A Torbicki; T Kraska
Journal:  Clin Cardiol       Date:  1997-04       Impact factor: 2.882

Review 5.  Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data.

Authors:  Tim T Issac; Hisham Dokainish; Nasser M Lakkis
Journal:  J Am Coll Cardiol       Date:  2007-11-05       Impact factor: 24.094

6.  Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. The BEST AF Trial.

Authors:  B M Glover; S J Walsh; C J McCann; M J Moore; G Manoharan; G W N Dalzell; A McAllister; B McClements; D J McEneaney; T G Trouton; T P Mathew; A A J Adgey
Journal:  Heart       Date:  2007-06-25       Impact factor: 5.994

7.  Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction.

Authors:  D L Packer; G H Bardy; S J Worley; M S Smith; F R Cobb; R E Coleman; J J Gallagher; L D German
Journal:  Am J Cardiol       Date:  1986-03-01       Impact factor: 2.778

Review 8.  Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2012-01-01       Impact factor: 11.431

9.  Suitability, efficacy, and safety of vernakalant for new onset atrial fibrillation in critically ill patients.

Authors:  Alain Rudiger; Alexander Breitenstein; Mattia Arrigo; Sacha P Salzberg; Dominique Bettex
Journal:  Crit Care Res Pract       Date:  2014-05-12

Review 10.  Management of atrial fibrillation in critically ill patients.

Authors:  Mattia Arrigo; Dominique Bettex; Alain Rudiger
Journal:  Crit Care Res Pract       Date:  2014-01-16
View more
  1 in total

1.  [Emergency treatment of tachycardias].

Authors:  N Deubner; H Greiss; T Neumann
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-03-24       Impact factor: 0.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.